OncoMatch/Clinical Trials/NCT05104515
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
Is NCT05104515 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies OVM-200 for prostate cancer.
Treatment: OVM-200 — OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in patients with cancer. The Study consists of 2 parts: a dose escalation part and a dose expansion part. In the dose escalation part, up to 4 increasing doses of OVM-200 will be evaluated in small groups of cancer patients to find the recommended dose for the expansion part. The recommended dose of OVM-200 will then be given to cancer patients in the dose expansion part to confirm safety and understand how effective it is against their disease and if there are any side effects. Patients who agree to participate in the Study and pass screening will receive 3 doses of OVM-200 in total at 2-week intervals as an injection under the skin. After completing treatment with OVM-200 patients will be followed up for side effects and to monitor changes in their cancer. Patients will stay on the Study for about 6 months in total during which they will have 10 hospital visits. The Study will run at around 5 sites in the UK.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Small Cell Lung Cancer
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: approved cancer therapy
have already received at least 1 line of approved cancer therapy
Cannot have received: anticancer vaccine
Prior therapy with an anticancer vaccine
Cannot have received: anti-PD-1 therapy
anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody; or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways in the 28 days before the first dose of study drug
Cannot have received: investigational drug
Administration of an investigational drug in the 28 days or 6 half-lives (whichever is longer) before the first dose of study drug
Cannot have received: chemotherapy
treatment with any chemotherapy...in the 28 days before the first dose of study drug
Cannot have received: radiation therapy
treatment with any...radiation therapy for cancer in the 28 days before the first dose of study drug
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify